DSpace Repository

Paclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix

Show simple item record

dc.contributor.author Tangjitgamol S.
dc.contributor.author Manusirivithaya S.
dc.contributor.author Choomchuay N.
dc.contributor.author Leelahakorn S.
dc.contributor.author Thawaramara T.
dc.contributor.author Pataradool K.
dc.contributor.author Suekwatana P.
dc.date.accessioned 2021-04-05T04:32:12Z
dc.date.available 2021-04-05T04:32:12Z
dc.date.issued 2007
dc.identifier.issn 13418076
dc.identifier.other 2-s2.0-33847713390
dc.identifier.uri https://ir.swu.ac.th/jspui/handle/123456789/14953
dc.identifier.uri https://www.scopus.com/inward/record.uri?eid=2-s2.0-33847713390&doi=10.1111%2fj.1447-0756.2007.00509.x&partnerID=40&md5=f5ff88a7c610ad00771b079509002ba5
dc.description.abstract The prognosis of large cell neuroendocrine carcinoma (LCNEC) of the uterine cervix is generally poor despite multimodality of treatments. We report a case of advanced stage cervical LCNEC that showed definite response to paclitaxel/carboplatin, resulting in years of survival. The patient was referred to our institution after undergoing a simple hysterectomy with bilateral salpingo-oophorectomy in her local hospital because of a ruptured metastatic ovarian mass. She declined pelvic radiation treatment, so adjuvant chemotherapy (six cycles of paclitaxel/carboplatin) was given for the residual pelvic nodal diseases. Clinical complete remission was obtained, with a disease-free period of 19 months. Systemic recurrent diseases also showed partial response to the same drug regimen for months with only minimal toxicity. However, she subsequently had progressive diseases in the liver and brain and finally died at 44 months after primary diagnosis and 19 months after recurrent diseases. © 2007 The Authors.
dc.subject carboplatin
dc.subject cisplatin
dc.subject etoposide
dc.subject paclitaxel
dc.subject adrenal metastasis
dc.subject adult
dc.subject article
dc.subject aspiration biopsy
dc.subject brain metastasis
dc.subject cancer chemotherapy
dc.subject cancer regression
dc.subject cancer staging
dc.subject cancer survival
dc.subject case report
dc.subject clinical feature
dc.subject computer assisted tomography
dc.subject disease free interval
dc.subject drug response
dc.subject drug substitution
dc.subject female
dc.subject histopathology
dc.subject human
dc.subject human tissue
dc.subject hysterectomy
dc.subject laboratory test
dc.subject large cell carcinoma
dc.subject liver metastasis
dc.subject lymph node metastasis
dc.subject multiple cycle treatment
dc.subject neuroendocrine tumor
dc.subject ovary tumor
dc.subject recurrent disease
dc.subject salpingooophorectomy
dc.subject unspecified side effect
dc.subject uterine cervix carcinoma
dc.subject Adult
dc.subject Antineoplastic Agents
dc.subject Antineoplastic Agents, Phytogenic
dc.subject Brain Neoplasms
dc.subject Carboplatin
dc.subject Carcinoma, Large Cell
dc.subject Carcinoma, Neuroendocrine
dc.subject Chemotherapy, Adjuvant
dc.subject Combined Modality Therapy
dc.subject Disease Progression
dc.subject Fatal Outcome
dc.subject Female
dc.subject Humans
dc.subject Liver Neoplasms
dc.subject Neoplasm Recurrence, Local
dc.subject Ovariectomy
dc.subject Paclitaxel
dc.subject Uterine Cervical Neoplasms
dc.title Paclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix
dc.type Article
dc.rights.holder Scopus
dc.identifier.bibliograpycitation Journal of Obstetrics and Gynaecology Research. Vol 33, No.2 (2007), p.218-224
dc.identifier.doi 10.1111/j.1447-0756.2007.00509.x


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics